Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903119 · ClinicalTrials.gov registry record · Phase 1
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
A Phase 1 study of Metastatic Melanoma and BRAF Gene Mutation, sponsored by Rina Plattner.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT04903119 is a Phase 1 study of Metastatic Melanoma and BRAF Gene Mutation that is actively recruiting participants, run by Rina Plattner. The registered enrollment target is 30 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (64% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04903119, a Phase 1 study of Metastatic Melanoma and BRAF Gene Mutation, is actively recruiting participants, sponsored by Rina Plattner.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerability and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and trametinib or with encorafenib and binimetinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and nilotinib when used in combination.
Conditions Studied
Interventions
- DRUG Dabrafenib
- DRUG Nilotinib 100mg
- DRUG Nilotinib 200mg
- DRUG Nilotinib 300mg
- DRUG Nilotinib 400mg
Study Locations (4)
Iowa
- University of Iowa - Iowa City
Kentucky
- Markey Cancer Center - Lexington
Pennsylvania
- St. Luke's University Health Network - Easton
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903119
The ClinicalTrials.gov registry entry for NCT04903119 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (64% lower). The listed sponsor is Rina Plattner, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Dabrafenib is the first listed.
NCT04903119 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Iowa, Kentucky, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04903119 about?
NCT04903119 is a clinical study titled "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma". This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerabi...
What is the current status of trial NCT04903119?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-06-01. Estimated completion is 2030-06-01.
What conditions does trial NCT04903119 study?
This clinical trial studies the following conditions: Metastatic Melanoma, BRAF Gene Mutation.
What interventions are being tested in trial NCT04903119?
The interventions under investigation include: Dabrafenib (DRUG), Nilotinib 100mg (DRUG), Nilotinib 200mg (DRUG), Nilotinib 300mg (DRUG), Nilotinib 400mg (DRUG).
Who is sponsoring clinical trial NCT04903119?
This trial is sponsored by Rina Plattner, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04903119 being conducted?
This trial has 4 study locations across Iowa, Kentucky, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.